Related Experiment Video
Updated: Jun 14, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Molecular response prediction in gastrointestinal stromal tumors
Philippe A Cassier1, Jean-Yves Blay
1Département de Médecine, Centre Léon Bérard, Lyon, France.
Abstract:
Gastrointestinal stromal tumors (GISTs) are rare tumors of mesenchymal origin that develop along the gastrointestinal tract. Over ten years ago, their management dramatically changed following the discovery of an activating mutation of the KIT oncogene, which led to the use of small molecule inhibitors to therapeutically target these mutant kinases. Patients with advanced GIST, who were once a subset of sarcoma with poor prognosis due to their lack of chemosensitivity, may now survive more than 5 years following treatment with tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM) and sunitinib malate (SU). After ten years of active clinical and preclinical research, it has become clear that, although relatively homogeneous compared to other solid malignancies, there is still some heterogeneity in GISTs and most notably in regard to response to therapy. Here, we review the current data regarding molecular prediction of response in this disease.
Insights
Gastrointestinal stromal tumors (GISTs) are rare. KIT oncogene mutations led to targeted therapies like imatinib, improving survival for advanced GIST patients. Molecular markers predict treatment response.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms.
- KIT oncogene mutations drive GIST development and therapeutic targeting.
- Tyrosine kinase inhibitors (TKIs) have transformed advanced GIST management.
Purpose of the Study:
- To review current data on molecular markers for predicting GIST response to therapy.
- To highlight the heterogeneity in GIST response despite molecular homogeneity.
- To consolidate knowledge on molecular prediction of treatment outcomes in GIST.
Main Methods:
- Literature review of clinical and preclinical research on GIST.
- Analysis of data on molecular alterations and their correlation with TKI response.
- Synthesis of information on therapeutic strategies and resistance mechanisms.
Main Results:
- Activating KIT mutations are key drivers, with specific mutations influencing TKI efficacy.
- Heterogeneity exists in GIST, impacting individual patient responses to targeted therapies.
- Molecular profiling is crucial for predicting treatment outcomes and guiding therapy selection.
Conclusions:
- Molecular prediction of response is vital for optimizing GIST treatment.
- Understanding GIST heterogeneity aids in personalized therapeutic approaches.
- Continued research into molecular markers will further refine GIST management.
